The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.
Additional follow-up data from the phase 2 MorningSun study showed a 91.9% overall survival rate for previously untreated patients with high-tumor burden follicular
Researchers found that the addition of lenalidomide before apheresis improved pharmacodynamics in patients with multiple myeloma (MM) undergoing autologous hematopoietic cell transplantation (AHCT).
A phase 1/2, first-in-human study showed that the investigational agent LBL-034 induced a response in 70.9% of patients (n=39/55) with relapsed/refractory multiple myeloma
A first-in-human study of the menin inhibitor DS-1594b in patients with acute leukemias was discontinued early due to lack of efficacy as a
An ongoing phase 1 study observed an 86% overall response rate (ORR) in patients with multiple myeloma (MM) treated with the novel trispecific
A phase 1b/2 study added the investigational BCL-2 inhibitor lisaftoclax to pomalidomide/dexamethasone (Pd) and daratumumab/lenalidomide/dexamethasone (DRd) regimens and observed improved outcomes in patients
A study presented by Saad Usmani, MD, MBA, of the Memorial Sloan Kettering Cancer Center, as part of the SOHO 2025 Annual Meeting,
Results from the phase 1/2 CA057-003 study showed early efficacy and safety with the addition of mezigdomide to novel combinations for relapsed or
The phase 3 MagnetisMM-6 study showed a manageable safety profile and high response rates in transplant-ineligible, newly diagnosed multiple myeloma (MM) patients treated
Ongoing results from the DREAMM-8 trial reinforced the clinically meaningful progression-free survival (PFS) benefit of belantamab mafodotin, pomalidomide, and dexamethasone (BPd) versus pomalidomide,
